經(jīng)口膽道鏡聯(lián)合經(jīng)皮膽道穿刺引流會師術治療Beger術后膽瘺1例報告
摘要:保留十二指腸胰頭局部切除術(Beger術)術后膽管損傷發(fā)生率較高,而膽管損傷的治療方式取決于損傷嚴重程度,內(nèi)鏡治療在膽管損傷嚴重的情況下較困難。近期西湖大學附屬杭州市第一人民醫(yī)院收治1例因Beger術后出現(xiàn)膽瘺的患者,通過經(jīng)口膽道鏡聯(lián)合經(jīng)皮膽道穿刺引流會師術成功診治,取得良好效果。
關鍵詞:膽瘺;穿刺抽液術;胰膽管造影術,內(nèi)窺鏡逆行
基金項目:杭州市重點醫(yī)學學科建設基金(OO20190001)
Successful treatment of biliary fistula after Beger surgery by oral choledochoscopy-assisted percutaneous-endoscopic rendezvous technique:A case report
WANG Yuxin1,2,GU Weigang2,JIN Zheng2,ZHANG Xiaofeng1,2,3,4
1.The Fourth Clinical Medical College of Zhejiang Chinese Medical University,Hangzhou 310003,China;2.Department of Gastroenterology,Affiliated Hangzhou First People’s Hospital,Westlake University School of Medicine,Hangzhou 310058,China;3.Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province,Hangzhou 310006,China;4.Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province,Hangzhou 310058,China
Corresponding author:ZHANG Xiaofeng,19883201892@163.com(ORCID:0009-0007-1858-8905)
Abstract:Duodenum-preserving pancreatic head resection,also known as Beger surgery,has a high incidence rate of bile duct injury after surgery,while the treatment modality for bile duct injury depends on the severity of the injury,and endoscopic therapy is often challenging in case of severe bile duct injury.Recently a patient with biliary fistula after Beger surgery was admitted to Affiliated Hangzhou First People’s Hospital,Westlake University,and successful diagnosis and treatment were achieved through oralcholedochoscopy-assisted percutaneous-endoscopic rendezvous technique.
Key words:Biliary Fistula;Paracentesis;Cholangiopancreatography,Endoscopic Retrograde
Research funding:The Construction Fund of Key Medical Disciplines of Hangzhou(OO20190001)
1病例資料
患者男性,42歲,因“Beger術后1個月,皮膚、鞏膜黃染10天”于2023年11月29日就診于西湖大學附屬杭州市第一人民醫(yī)院。(剩余5836字)
- 建立公共衛(wèi)生管理模式,促進消除...
- 中國慢性乙型肝炎治療的進展與挑...
- 中國乙型肝炎疫苗免疫策略及接種...
- 中國消除丙型肝炎公共衛(wèi)生危害行...
- 中國病毒性肝炎疾病負擔研究進展...
- 海南省消除病毒性肝炎公共衛(wèi)生危...
- 《2024年歐洲肝病學會臨床實...
- 《2024年歐洲肝病學會臨床實...
- 基于限制性立方樣條模型分析絕經(jīng)...
- 1,25(OH)2D3改善膽堿...
- 不同無創(chuàng)診斷模型對代償期乙型肝...
- 丙型肝炎肝硬化失代償患者再代償...
- 合并肝細胞癌對肝硬化食管胃靜脈...
- 線粒體翻譯起始因子(MTIF2...
- 五倍子酸對肝癌HepG2細胞索...
- 鱉甲煎丸調(diào)控AKT/mTOR信...
- 62例不明原因肝內(nèi)膽汁淤積的病...
- 基于CT圖像的腹部肌肉內(nèi)部分層...
- 層粘連蛋白α3亞基(LAMA3...
- 經(jīng)口膽道鏡聯(lián)合經(jīng)皮膽道穿刺引流...
- 幽門螺桿菌感染與HBV感染相關...
- HBV感染與線粒體穩(wěn)態(tài)相互作用...
- 中藥調(diào)控免疫細胞治療肝細胞癌的...
- 肝細胞癌合并膽管癌栓的診療進展...
- 慢性膽汁淤積性肝病基礎上發(fā)生藥...
- 肝性腦病中醫(yī)/壯醫(yī)“濁毒致病”...
- 生物堿類化合物調(diào)控慢性肝病的作...
- 髓系細胞觸發(fā)受體2(TREM2...
- 自噬在對乙酰氨基酚誘導肝損傷中...
- 自身免疫性胰腺炎合并胰腺外分泌...
- Hepatology|多中心、...
- Journal of Hepa...
- Journal of Hepa...
- Liver Internati...
- 《臨床肝膽病雜志》關于利益沖突...
- 《臨床肝膽病雜志》關于倫理審查...
- 《臨床肝膽病雜志》入選“中國科...
- 《臨床肝膽病雜志》2025年1...
- 《臨床肝膽病雜志》入選“全球O...
- 《臨床肝膽病雜志》入選“中國開...
- 《臨床肝膽病雜志》入選“學術誠...
- 本期審稿專家...